首页 › 基金 › Affinity Asset Advisors, LLC › ARWR
Affinity Asset Advisors, LLC 对 ARWR 的持仓历史
ARROWHEAD PHARMACEUTICALS IN · 医疗保健
Affinity Asset Advisors, LLC 在 Q3 2026 的 13F 申报中披露持有 ARWR(ARROWHEAD PHARMACEUTICALS IN)425,000 股,市值约 US$27.8M,约占其申报组合的 1.30%,在其申报持仓中市值排名第 21 位。 Affinity Asset Advisors, LLC 最近 11 个申报季度中有 8 个季度披露了 ARWR 持仓,最早可追溯至 Q1 2024。
最后更新: 2026-11-14 · 来源: SEC EDGAR Form 13F-HR
Affinity Asset Advisors, LLC 对 ARWR 的持仓演变
Affinity Asset Advisors, LLC 于 Q1 2024 首次披露 ARWR 持仓:120,000 股(约 US$3.4M)。 该持仓在 Q3 2026 达到峰值 425,000 股,市值约 US$27.8M。 在 8 次申报中,Affinity Asset Advisors, LLC 3 次增持、3 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 425,000 股、市值约 US$27.8M,环比增持 275,000 股。。 持仓曾出现大幅变动:Q3 2024 增持约 550% (随后一个季度股价下跌 3%)、Q1 2026 增持约 186% (随后一个季度股价上涨 30%)、Q3 2026 增持约 183% (随后一个季度股价下跌 27%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2024 | 120.00K | $3.43M | 新进 |
| Q2 2024 | 50.00K | $1.30M | 减持 |
| Q3 2024 | 325.00K | $6.30M | 增持 |
| Q4 2024 | 300.00K | $5.64M | 减持 |
| Q4 2025 | 70.00K | $4.65M | 新进 |
| Q1 2026 | 200.00K | $12.54M | 增持 |
| Q2 2026 | 150.00K | $12.23M | 减持 |
| Q3 2026 | 425.00K | $27.82M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 ARWR 与 13F 数据
ARWR(ARROWHEAD PHARMACEUTICALS IN)属于医疗保健行业。我们追踪的基金中还有 43 只申报持有 ARWR,申报仓位最大的包括:Avoro Capital Advisors LLC (US$925.6M), FRED ALGER MANAGEMENT, LLC (US$269.1M), BAKER BROS. ADVISORS LP (US$162.4M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 ARWR 的基金
- Avoro Capital Advisors LLC 11.36M 股 · $925.59M · Q2 2026
- FRED ALGER MANAGEMENT, LLC 3.30M 股 · $269.14M · Q2 2026
- BAKER BROS. ADVISORS LP 1.99M 股 · $162.43M · Q2 2026
- Siren, L.L.C. 2.29M 股 · $149.91M · Q3 2026
- Vestal Point Capital, LP 1.57M 股 · $128.38M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.39M 股 · $113.22M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 1.35M 股 · $110.08M · Q2 2026
- Hood River Capital Management LLC 1.12M 股 · $91.35M · Q2 2026
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 830.25K 股 · $67.67M · Q2 2026
- Western Financial Corp/CA 820.24K 股 · $53.68M · Q3 2026
- READYSTATE ASSET MANAGEMENT LP 25.00M 股 · $29.94M · Q2 2026
- MACKAY SHIELDS LLC 27.19M 股 · $27.84M · Q3 2026
更多关于 Affinity Asset Advisors, LLC
常见问题
How long has Affinity Asset Advisors, LLC held ARWR?
Affinity Asset Advisors, LLC has disclosed ARWR holdings in 8 of the last 11 reported quarters, going back to Q1 2024.
What is Affinity Asset Advisors, LLC's current position in ARWR?
As of Q3 2026, Affinity Asset Advisors, LLC holds 425.00K shares of ARWR (ARROWHEAD PHARMACEUTICALS IN), valued at $27.82M, representing 1.30% of its reported portfolio and ranking #21.
Has Affinity Asset Advisors, LLC been buying or selling ARWR?
In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC increased its position in ARWR. The position peaked in Q3 2026 at 425.00K shares.
Which other funds hold ARWR?
Other major institutional holders of ARWR include Avoro Capital Advisors LLC, FRED ALGER MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.